Preclinical efficacy of multi-targeting mRNA-based CAR T cell therapy in resection models of glioblastoma.

ABSTRACT: Traditional viral-based chimeric antigen receptor (CAR) T cell therapies have vanquished multiple blood malignancies with decade-long remissions yet struggle against solid tumors. Nonviral engineering of CAR T cells via electroporation or lipid nanoparticle (LNP) delivery of CAR-encoding mRNA results in highly efficient yet transient CAR expression, challenging the adequacy of available preclinical models for mRNA-based CAR T cell evaluation. This study presents a unique three-pronged approach that combines mRNA-based CAR T cells, multi-targeting of glioblastoma (GBM)-associated receptors, and maximal surgical resection as a novel and readily translatable platform for preclinical evaluation of mRNA-based CAR T cells against solid tumors. We performed head-to-head in vitro and in

SUBMITTER: Dagher OK 

PROVIDER: S-EPMC12397939 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature